Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium

BACKGROUND: The hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher-risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low-risk and intermediate-1– risk MDS by the International Prognostic Sco...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer
Egile Nagusiak: Jabbour, Elias J., Garcia-Manero, Guillermo, Strati, Paolo, Mishra, Asmita, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey, Kadia, Tapan, Daver, Naval, O'Brien, Susan, Steensma, David P., Sekeres, Mikkael A., Gore, Steven D., Dezern, Amy, Roboz, Gail J., List, Alan F., Kantarjian, Hagop M., Komrokji, Rami S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378905/
https://ncbi.nlm.nih.gov/pubmed/25410759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29145
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak